The Wegovy weight loss pill, a groundbreaking daily oral form of semaglutide from Novo Nordisk, launched in early January 2026 following FDA approval in December 2025, providing a convenient needle-free alternative for adults managing obesity or overweight with related health conditions. By mimicking the GLP-1 hormone, this semaglutide-based treatment curbs appetite, delays gastric emptying, and […]